ZTS

In the past six months (April 2026 - October 2026), Zoetis's stock price declined by almost 50% over the year, from $145.36 on October 6, 2025, to $69.69 on October 2, 2026. This significant drop, reaching 52% from its 52-week high, was attributed to stalled growth in next-generation osteoarthritis medicines for dogs and cats, continued declines in U.S. veterinary visits, intensified competition, and demand softness, particularly in the U.S. Companion Animal segment. In September 2026, Zoetis maintained its revised guidance for operational revenue, expecting a decline of 1% to 3%. Despite these challenges, positive developments included a declared dividend of $0.53 per share for the fourth quarter of 2026 on October 8, 2026. A new peer-reviewed publication on October 6, 2026, highlighted Simparica Trio®'s effectiveness against resistant heartworm. The company announced its second-quarter 2026 results on August 6, 2026, and received Emergency Use Authorization for Simparica Trio® for New World Screwworm infestations on August 13, 2026. Towards the end of the period, on October 9, 2026, ZTS stock was up +2.37% at $74.81, outpacing the S&P 500's gain.